Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
BackgroundFor patients with extensive-stage small cell lung cancer (ES-SCLC), serplulimab plus chemotherapy is beneficial as the first-line treatment. It is uncertain whether serplulimab plus chemotherapy will be more cost-effective. The aim of this study was to evaluate from the perspective of the...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2023-08-01
|
| シリーズ: | Frontiers in Public Health |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fpubh.2023.1156427/full |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|